Human kallikrein 6 (hK6): A new potential serum biomarker for diagnosis and prognosis of ovarian carcinoma

Journal of Clinical Oncology

Volumn 21, Issue 6, 2003, Pages 1035-1043

  Diamandis, Eleftherios P ^a   Scorilas, Andreas ^b   Fracchioli, Stefano ^b   Van Gramberen, Marleen ^b   De Bruijn, Henk ^b   Henrik, Alfthan ^b   Soosaipillai, Antoninus ^b   Grass, Linda ^b   Yousef, George M ^b   Stenman, Ulf Hakan ^b   Massobrio, Marco ^b   Van Der Zee, Ate G J ^b   Vergote, Ignace ^b   Katsaros, Dionyssios ^b  

^a MOUNT SINAI HOSPITAL   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

KALLIKREIN; KALLIKREIN 6; UNCLASSIFIED DRUG; CA 125 ANTIGEN; TISSUE KALLIKREIN; TUMOR MARKER;

ARTICLE; CANCER DIAGNOSIS; CANCER STAGING; CONTROLLED STUDY; DISEASE MANAGEMENT; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVARY CARCINOMA; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS; ADULT; AGED; ANALYSIS OF VARIANCE; BLOOD; CARCINOMA; COMPARATIVE STUDY; DIFFERENTIAL DIAGNOSIS; DISEASE FREE SURVIVAL; IMMUNOASSAY; MIDDLE AGED; MORTALITY; OVARY DISEASE; OVARY TUMOR; PATHOLOGY; PREDICTION AND FORECASTING; SENSITIVITY AND SPECIFICITY; SURVIVAL;

ADULT; AGED; ANALYSIS OF VARIANCE; CA-125 ANTIGEN; CARCINOMA; DIAGNOSIS, DIFFERENTIAL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOASSAY; MIDDLE AGED; NEOPLASM STAGING; OVARIAN DISEASES; OVARIAN NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; TISSUE KALLIKREINS; TUMOR MARKERS, BIOLOGICAL;

EID: 0037445253     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.02.022     Document Type: Article

References (49)

1. Greenlee RT, Hill Harmon M, Murray T, et al: Cancer statistics 2001. CA Cancer J Clin 51:15-36, 2001
2. Myer T, Rustin GJS: Role of tumor markers in monitoring epithelial ovarian cancer. Br J Cancer 82:1535-1538, 2000
3. Bast RC, Feeny M, Lazarus H, et al: Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 68:1331-1337, 1981
4. Bast RC, Klug TL, John ES, Al E: A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 309:883-887, 1983
5. Rustin GJ, Nelstrop A, Stilwell J, et al: Savings obtained by CA125 measurements during therapy for ovarian carcinoma. The North Thames Ovary Group. Eur J Cancer 28:79-82, 1992
6. Rustin GJ, Nelstrop AE, McClean P, et al: Defining response of ovarian carcinoma in initial chemotherapy according to serum CA125. J Clin Oncol 14:1545-1551, 1996
7. Eisenhauer EA, Vermerken JB, van Glabbeke M: Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer. A multivariate analysis of 704 patients. Ann Oncol 8:963-968, 1997
8. Nagele F, Petru E, Medl M, et al: Preoperative CA125: An independent prognostic factor in patients with stage I epithelial ovarian cancer. Obstet Gynecol 86:259-264, 1995
9. Jacobs I, Oram D, Fairbanks J, et al: A risk of malignancy index incorporating CA125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. Br J Obstet Gynaecol 97:922-929, 1990
10. Gadducci A, Baichhi U, Marrai R, et al: Preoperative evaluation of D-dimer and CA125 levels in differentiating benign from malignant ovarian masses. Gynecol Oncol 60:197-202, 1996
11. Woolas RP, Xu FJ, Jacobs IJ, et al: Elevation of multiple serum markers in patients with stage I ovarian cancer. J Natl Cancer Inst 85:1748-1751, 1993
12. Woolas RP, Conaway MR, Xu F, et al: Combinations of multiple serum markers are superior to individual assays for discriminating malignant from benign pelvic masses. Gynecol Oncol 59:111-116, 1995
13. Mok SC, Chao J, Skates S, et al: Prostasin, a potential serum marker of ovarian cancer: Identification through microarray technology. J Natl Cancer Inst 93:1458-1464, 2001
14. Einhorn N, Sjovall K, Knapp RC, et al: Prospective evaluation of serum CA125 levels for early detection of ovarian cancer. Obstet Gynecol 80:14-18, 1992
15. Jacobs I, Davies AP, Bridges J, et al: Prevalence screening for ovarian cancer in postmenopausal women by CA125 measurement and ultrasonography. Br Med J 306:1030-1032, 1993
16. Jacobs IJ, Skates SJ, MacDonald N, et al: Screening for ovarian cancer: A pilot randomised controlled trial. Lancet 353:1207-1210, 1999
17. Skates SJ, Xu F, Yu Y, et al: Toward an optimal algorithm for ovarian cancer screening with longitudinal tumour markers. Cancer 76:2004-2010, 1995
18. Welsh JB, Zarrinkar PP, Sapinoso LM, et al: Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. Proc Natl Acad Sci U S A 98:1176-1181, 2001
19. Schummer M, Ng WV, Bumgarner RE, et al: Comparative hybridization of an array of 21,500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas. Gene 238:375-385, 1999
20. Kim JH, Skates SJ, Uede T, et al: Osteopontin as a potential diagnostic biomarker for ovarian cancer. J Am Med Assoc 287:1671-1679, 2002
21. Khan J, Wei JS, Ringner M, et al: Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks. Nat Med 7:673-679, 2001
22. Diamandis EP, Yousef GM, Luo LY, et al: The human kallikrein gene family-implications in carcinogenesis. Trends Endocrinol Metab 11:54-60, 2000
23. Yousef GM, Diamandis EP: The new human tissue kallikrein gene family: Structure, function and association to disease. Endocr Rev 22:184-204, 2001
24. Diamandis EP: Prostate specific antigen-its usefulness in clinical medicine. Trends Endocrinol Metab 9:310-316, 1998
25. Barry MJ: Clinical practice: Prostate-specific antigen testing for early diagnosis of prostate cancer. N Engl J Med 344:1373-1377, 2001
26. Rittenhouse HG, Finlay JA, Mikolzjczyk SD, et al: Human kallikrein 2 (hK2) and prostate-specific antigen (PSA): Two closely related, but distinct, kallikreins in the prostate. Crit Rev Clin Lab Sci 35:275-368, 1998
27. Diamandis EP, Yousef GM, Soosaipillai AR, et al: Human kallikrein 6 (zyme/protease M/neurosin): A new serum biomarker of ovarian carcinoma. Clin Biochem 33:579-583, 2000
28. Obiezu CV, Scorilas A, Katsaros D, et al: Higher human kallikrein gene 4 (KLK4) expression indicates poor prognosis of ovarian cancer patients. Clin Cancer Res 7:2380-2386, 2001
29. Kim H, Scorilas A, Katsaros D, et al: Human kallikrein gene 5 (KLK5) expression is an indicator of poor prognosis in ovarian cancer. Br J Cancer 84:643-650, 2001
30. Magklara A, Scorilas A, Katsaros D, et al: The human KLK8 (neuropsin/ovasin) gene: Identification of two novel splice variants and its prognostic value in ovarian cancer. Clin Cancer Res 7:806-811, 2001
31. Luo LY, Katsaros D, Scorilas A, et al: Prognostic value of human kallikrein 10 expression in epithelial ovarian carcinoma. Clin Cancer Res 7:2372-2379, 2001
32. Luo L-Y, Bunting P, Scorilas A, Diamandis EP: Human kallikrein 10: A novel tumor marker for ovarian carcinoma? Clin Chim Acta 306:111-118, 2001
33. Dong Y, Kaushal A, Bui L, et al: Human kallikrein 4 (KLK4) is highly expressed in serous ovarian carcinomas. Clin Cancer Res 7:2363-2371, 2001
34. Tanimoto H, Underwood LJ, Shigemasa K, et al: The stratum corneum chymotryptic enzyme that mediates shedding and desquamation of skin cells is highly overexpressed in ovarian tumor cells. Cancer 86:2074-2082, 1999
35. Underwood LJ, Tanimoto H, Wang Y, et al: Cloning of tumor-associated differentially expressed gene-14, a novel serine protease overexpressed by ovarian carcinoma. Cancer Res 59:4435-4439, 1999
36. Yousef GM, Kyriakopoulou LG, Scorilas A, et al: Quantitative expression of the human kallikrein gene 9 (KLK9) in ovarian cancer: A new independent and favorable prognostic marker. Cancer Res 161:7811-7818, 2001
37. Diamandis EP, Yousef GM, Soosaipillai AR, et al: Immunofluorometric assay of human kallikrein 6 (zyme/protease M/neurosin) and preliminary clinical applications. Clin Biochem 33:369-375, 2000
38. Scholler N, Fu N, Yang Y, et al: Soluble member(s) of the mesothelin/megakaryocyte potentiating family are detectable in sera from patients with ovarian carcinoma. Proc Natl Acad Sci U S A 96:11531-11536, 1999
39. Mills GB, Bast RC, Srivastava S: Future for ovarian cancer screening: Novel markers for emerging technologies of transcriptional profiling and proteomics. J Natl Cancer Inst 93:1437-1439, 2001
40. Parley PJ: Ovarian cancer screening: Are we making any progress? Curr Opin Oncol 13:399-402, 2001
41. Hoffman BR, Katsaros D, Scorilas, et al: Immunofluorometric quantitation and histochemical localization of kallikrein 6 protein in ovarian cancer tissues: A new independent unfavorable prognostic biomarker. Br J Cancer 87:763-771, 2002
42. Shigemasa K, Underwood LJ, Beard J, et al: Overexpression of testisin, a serine protease expressed by testicular germ cells, in epithelial ovarian tumor cells. J Soc Gynecol Investig 7:358-362, 2000
43. Tanimoto H, Yan Y, Clarke J, et al: Hepsin, a cell surface serine protease identified in hepatoma cells, is overexpressed in ovarian cancer. Cancer Res 57:2884-2887, 1997
44. Hirahara F, Miyagi E, Nagashima Y, et al: Differential expression of trypsin in human ovarian carcinomas and low-malignant-potential tumors. Gynecol Oncol 68:162-165, 1998
45. Duffy MJ: Role of proteolytic enzymes in cancer invasion and metastasis. Clin Exp Metastasis 10:145-155, 1992
46. Matrisian LM: Cancer biology: Extracellular proteinases in malignancy. Curr Biol 9:R776-R778, 1999
47. Kleiner DE, Stetler-Stevenson WG: Matrix metalloproteinases and metastasis. Cancer Chemother Pharmacol 43:S42-S51, 1999
48. Woodhouse EC, Chuaqui RF, Liotta LA: General mechanisms of metastasis. Cancer 80:1529-1537, 1997
49. Aznavoorian S, Murphy AN, Stetler-Stevenson WG, et al: Molecular aspects of tumor cell invasion and metastasis. Cancer 71:1368-1383, 1993